pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
479
stories
Jul 20, 26
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
biospace
Jul 17, 26
Compounders maintain a firm grip on the GLP-1 market
biopharma dive
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 15, 26
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
stat
Jul 14, 26
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
biopharma dive
Jul 14, 26
STAT+: Akero team, backed by Fairmount, launches new immunology company
stat
Jul 14, 26
Former Akero team announces new I&I company, Avere, with China drug
endpoints
Jul 10, 26
STAT+: Roche ends Huntington’s gene-silencing programs
stat
Jul 10, 26
The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapy
endpoints
Jul 9, 26
Catalent to divest UK site; Rottendorf, Evonik announce manufacturing builds
endpoints
Jul 9, 26
Opinion: Who benefits from classifying obesity as a disease?
stat
Jul 8, 26
STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
stat
Jul 7, 26
Kailera says obesity pill succeeds in late-stage trial in China
biopharma dive
Jul 7, 26
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
stat
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jul 6, 26
STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
stat
Jul 2, 26
STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals
stat
Jul 2, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jul 2, 26
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
stat
Jul 2, 26
The new presidential fitness test is a positive step, not the solution, experts say
stat
Jul 1, 26
STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenes
stat
Jun 30, 26
Republican Tom Kean Jr. reveals depression diagnosis after his four-month absence from Congress
stat
Jun 30, 26
Half of states sue over Medicaid work requirements
stat
Jun 30, 26
STAT+: Even with MAHA, Trump administration has gone soft on alcohol
stat
Jun 30, 26
STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
stat
Jun 29, 26
5 takeaways from STAT’s investigation into microhospital operator Nutex Health
stat
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 20, 26
Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
endpoints
Jun 19, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jun 18, 26
STAT+: Eli Lilly ends 340B drug discounts to some hospitals for failing to provide claims data
stat
← prev
page 13 of 16
next →
